Incidence of adverse events similar to saline control1

  • Most commonly reported treatment-emergent adverse events (≥1%) in clinical studies including randomized, double-blind, parallel-group, placebo- and/or active-controlled, and pharmacokinetic/pharmacodynamic studies with follow-up ranging from 6 to 24 weeks
Bar graph comparing overall incidence of treatment-emergent adverse events for ZILRETTA and saline control, showing similar safety profiles
Mobile version of chart comparing overall adverse event rates between ZILRETTA and saline control
*

Incidence in which the adverse event rate is higher for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) than saline control.

Bar chart showing specific adverse events with slightly higher incidence in ZILRETTA-treated patients compared to saline control
Mobile-optimized chart highlighting treatment-emergent adverse events reported more frequently with ZILRETTA than saline

*Considered to be related to progression of osteoarthritis, rather than a treatment-related change, because appearance was nonspecific and severe joint space narrowing was observed for both the baseline and end-of-study radiographs.


ACR=American College of Rheumatology; KOOS QOL=Knee Injury and Osteoarthritis Outcomes Score–Quality of Life; OA=osteoarthritis; TEAEs=treatment-emergent adverse events;=Western Ontario and McMaster Universities Osteoarthritis Index.